Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HDM1002 in Hepatic Impairment
NCT06985615Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of conveglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Huadong Medicine. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time at 72 hours and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06985615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985615.